Skip to main content

Table 2 General characteristics IMM studies wherein patients were treated with SBRT

From: Stereotactic body radiotherapy for intramedullary metastases: a retrospective series at the Oscar Lambret center and a systematic review

Author and year Mean tumor volume in cubic centimeter Treatment modality Dose/fraction Median follow-up Overall survival Clinical outcome Radiological outcome Toxicities
Shin, 2009 [15] 1.52 LINAC 14 Gy (10–16 Gy) / 1 fraction 10 months 8 (2–19) months Improvement: 80%, Stable: 10%, Worse: 10% Complete: 22%, Partial: 33%, Stable: 33%, Progression: 11% None
Parikh, 2009 [9] NA CK 15 Gy/3 fractions 26 months 9,8 months Improvement Stable None
Dewas, 2011 [10] NA CK 20 Gy / 4 fractions 11 months NR Stable Stable None
Lieberson, 2012 [11] NA CK 27 Gy / 3 fractions 3 months 15 months Stable Complete None
Veeravagu, 2012 [16] 1.17 CK 21 Gy (14–27 Gy) / 3 fractions (1–5) NR 2 months Improvement: 11%, Stable: 44%, NA: 55% Partial: 22%, Stable: 22%, NA: 78% None
Mori et al., 2016 [12] NA VMAT 39 Gy / 13 fractions 5 months NR Improvement Partial None
Garcia, 2016 [13] 0.167 CK 17 Gy / 1 fraction 37 months 8 months Improvement Stable None
Barrie, 2019 [14] NA CK 25 Gy / 5 fractions 26 months 8 (0–65) months Stable Progression None
Ehret, 2021 [17] 1.1 CK 16 Gy (6–24 Gy) / 1 fraction (1–3) 8.5 months 11,7 months Improvement: 27%, Stable: 30%, Worse: 21% Complete: 79% patients with follow-up imaging None
Our series, 2021   CK 30 Gy (25–36 Gy) / 6 fractions (5–6) 23 months NR Improvement: 40%, Stable: 60% Complete: 25%, Partial: 50%, Stable: 25% None
  1. Abbreviations: CK, CyberKnife®; Gy, gray; NA, not available; NR, not reach
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us